Posts for Ticker ‘ENCY’

Major Biotech Movers (AGEN, CEGE, ENCY, IDMI, IMCL, ONXX, PFE, NTII, OXGN, PSDV, SIRT)

Antigenics Inc.  (NASDAQ: AGEN) A study for Cancer vaccine, Oncophage, for the treatment of metastatic melanoma showed mixed results this morning. Shares are down almost 7% to $2.17. The 52 week range is $1.54 to $5.42.

Cell Genesys, Inc. (NASDAQ: CEGE). Shares continue to climb following report Friday citing that vaccine candidate GCAX showed immune response in prostate cancer patients. Shares are trading at $2.93 in mid-day trading. The 52 week range is $1.78 to $7.30.

IDM Pharma, Inc. (NASDAQ: IDMI). Downgraded by Rodman & Renshaw. Shares plummet over 18% to $2.57. The 52 week range is $0.57 to $10.75.

Imclone Pharmaceuticals (NASDAQ: IMCL). Halted testing for competitor Onyx Pharmaceuticals (NASDAQ: ONXX) in the lung cancer drug market and a 4.96% stake purchase by Steve Cohen’s hedge fund, SAC Capital, pushed Imclone up early Tuesday. Shares have returned down to $38.41 in mid-day trading. The 52 week range is $27.50 to $47.94

Neurobiological Technologies Inc. (NASDAQ: NTII) Received a $2.1 million quarterly royalty payment for sales of Memantine, a moderate-to-severe Alzheimer’s disease treatment, from Merz Pharmaceuticals GmbH. Shares have showed little reaction, trading at $2.67. The 52 week range is $2.06 to $19.53.

Oxigene Inc. (NASDAQ: OXGN) Secures $40 million committed equity financing facility. Shares are down over 3% and trading in at $2.05 with a 52 week range of $2.01 to $5.12.

Onyx Pharmaceuticals (NASDAQ: ONXX). Shares are down by $3.47 to $29.62, a 10% drop after being murdered yesterday due to a Phase III testing halt for its lung cancer drug Nexavar. Shares fell almost 25% yesterday. The 52 week range is $23.65 to $61.18.

Today, Pfizer (NYSE: PFE) announced offer to buy all issued and outstanding shares of Encysive Pharmaceuticals (NASDAQ: ENCY) for $2.35 per share, a transaction valued at $195 million in equity. Pfizer will acquire the rights to THELIN, a treatment for PAH currently in pre-Phase III clinical testing in the United States. Pfizer is up almost $0.10 to $22.45 in mid-day trading. The range is $21.56 to $27.73. Encysive is up 110% to $2.27. The 52 week range is $0.59 to $5.02.

Psivida Ltd.  (NASDAQ: PSDV)  Received first R&D payments from Pfizer of $500,000 in part of an over $160 million agreement. Shares are down over 2% at $0.78. The 52 week range is $0.39 to $2.99.

Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT). Co-founder to present first In-Vivo, pre-clinical data showing SIRT1 activation has the ability to suppress tumor formation in cancer of the intestine and colon. Shares are down trading at $11.59 with a 52 week range of $9.81 to $21.99.

Rachel Lopez
February 20, 2008

Posted on: February 20, 2008 – 1:13 pm in Biotech, , , , , , , , , , ,

Pre-Market Earnings Gappers (November 2, 2007)

(ALY) Allis-Chalmers $0.37 EPS vs $0.36 est.
(ASVI) A.S.V. Inc. $0.13 EPS vs $0.19 est.
(BEBE) bebe stores traded up 3% despite slight revenue miss.
(CBB) Cincinnati Bell $0.09 EPS vs $0.08 est.
(CI) CIGNA $1.14 EPS vs $0.93 est.
(DUK) Duke Energy $0.48 EPS vs $0.39 est.
(ENCY) Encysive -$0.32 EPS vs -$0.31 est.
(ERTS) Electronic Arts trading up 3% after beating earnings.
(GYI) Getty Images traded up 5% after earnings.
(HAIN) Hain Celestial rose almost 5% after beating earnings expectations.
(HIMX) HIMAX trading up 7% after earnings.
(IP) International Paper $0.57 EP vs $0.57 est.
(ITRI) Itron trading down 11% after earnings.
(LVS) Las Vegas Sands trading down $16+ to $109 pre-market on net loss.
(MSO) Martha Stewart Enterprises -$0.08 EPS vs -$0.13 est.
(NI) NIsource $0.08 EPS vs $0.10 est.
(NTLS) NETELOS $0.18 EPS vs $0.14 est.
(NYX) NYSE $0.76 EPS vs. $0.73 est.
(OMG) OM Group $1.30 EPS vs $1.17 est.
(RDEN) Elizabeth Arden $0.04 EPS vs -$0.05 est.; sees Q2 $1.11-1.16 vs $1.21 est.
(SGMS) Scientific Games down 4% after earnings.
(SYNA) Synaptics traded up 10% after beating earnings expectations.
(VCLK) ValueClick trading down 0.5% after lackluster earnings.
(VIA) Viacom $0.65 vs 0.60

Posted on: November 2, 2007 – 7:31 am in Earnings, Pre-Market Activity, , , , , , , , , , , , , , , , , , , , , ,

The 52-Week Low Club

First Acceptance (FAC) Tough quarter for auto insurer. Drops to $4.94 from 52-week high of $11.77.

Bowater Incorporated (BOW) Loses abitration with Weyerhause. Down to 14.60 from 52-week high of $29.96. Business combination with Abitibi approved.

Abitibi-Price (ABY) Shareholders seem unhappy with marriage with Bowater. Down to $1.72 from 52-week high of $3.51.

Harley-Davidson (HOG) Bad numbers continue to dog the hog. Down to $46.35 from 52-week high of $75.87.

ACE*COMM (ACEC) Delisted from Nasdaq. Falls to $.42 from 52-week high of $1.92.

Neurobiological Technologies (NTII) Loss in last quarter. Drops to $.57 from 52-week high of $3.22.

Encysive Pharmaceuticals (ENCY) Biopharma drops to $1.46 from 52-week high of $7.10.

Douglas A. McIntyre

Posted on: September 14, 2007 – 3:29 pm in HI/LOW, , , , , , ,

Pre-Market Stock News (July 17, 2007)

(ADTN) Adtran $0.28 EPS versus $0.28 estimate.
(AIZ) Assurant CEO and CFO received SEC WELLS NOTICE.
(ASD) American Standard noted as a positive ahead of split-up by Cramer on MAD MONEY.
(CVO) Cenveo is acquiring Commercial Envelope.
(DJ) Dow Jones has reportedly reached some terms with News Corp. over the merger according to WSJ reports; actual status varies from source to source so consider this still an outstanding issue until formal statements are made from one or both companies.
(ELS) Equity Lifestyle $0.59 EPS vs $0.58 estimate.
(ENCY) Encysive retained Morgan Stanley to assist in strategic review.
(FCFS) First Cash Financial $0.27 EPS vs $0.26 estimate.
(JNJ) J&J $1.05 EPS vs $1.00 estimate.
(KEY) KeyCorp $0.86 EPS vs $0.70e; raised guidance as well, but unsure if comparable.
(KO) Coca-Cola $0.85 EPS vs. $0.82 estimate.
(LYO) Lyondell is being acquired by Basell for $48.00 per share.
(MDT) Medtronic received approval for artificial disc for the neck.
(MER) Merrill Lynch $2.24 EPS vs $2.02 estimate.
(NLS) Nautilus traded down 12% after earnings.
(PHTN) Photon Dynamics sees results under plan for Q3.
(PHG) Philips Electronics noted positively as European play by Cramer on MAD MONEY.
(RF) Regions Financial $0.69 EPS vs $0.69 estimate.
(STT) State Street $1.07 EPS vs $1.01 estimate.
(WFC) Wells Fargo unveiled a money transfer program.
(WGOV) Woodward Governor noted positively by Cramer on MAD MONEY.
(XLNX) Xilinx’s Spartan-3E and MicroBlaze soft processor selected for Samsung Electronics’ latest digital video surveillance system.

Jon C. Ogg
July 17, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: July 17, 2007 – 7:02 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , , , ,

Pre-Market Stock News (July 10, 2007)

(AA) Alcoa $0.81 EPS vs $0.81e; will likely have to sweeten Alcan bid before getting any approval from Alcan.
(BOT) CBOT holders approve the CME merger offer.
(CACS) Carrier Access lowered guidance.
(CAKE) Cheesecake Factory put revenues at $373.2 million vs $371 million consensus estimate.
(CVTX) CV Therapeutics identified possible anti-diabetic characteristics in Ranexa.
(DELL) Dell has new smaller business initiative being released today.
(ENCY) Encysive announced its CFO is resigning.
(FORM) Form Factor in strategic pact with Elpida for test cost reductions.
(GMST) Gemstar TV-Guide hired UBS to explore strategic alternatives.
(HD) Home Depot issued earnings warning, but stock called flat to marginally higher.
(LXK) Lexmark issued earnings warning.
(SHLD) Sears lowered guidance to %0.98-1.24 EPS (vs. $2.12 est.) because of home appliances and other sales being weaker; increased share buyback plan.
(THRX)  Theravance announced positive results from phase II clinical study that met primary endpoints fot staph and other skin based infections.
(UNCA) Unica lowered guidance.
(WDFC) WD-40 $0.44 EPS vs $0.47e; lowered annual EPS guidance.

Jon C. Ogg
July 10, 2007

Posted on: July 10, 2007 – 7:08 am in Pre-Market Activity, , , , , , , , , , , , , , , ,

Blackstone (BX) Joins The 52-Week Low Club

Blackstone (BX) It did just go public, but it should be doing better than this. $30.32, down from $38.

W Hldg (WHI) Bank holding company says one of its asset-backed loans is "impaired". Drops to $3.16 from 52-week high of $6.70.

Fortress Investment (FIG) Pulled down by Blackstone drop. Falls to $21.90 from 52-week high of $37.

Hovnanian (HOV), Pulte (PHM), Beazer (BZH), Lennar (LEN). On the list so often, might as well do them as a group. Housing gets worse.

US Energy Systems (USEY) Energy services provider looking at bankruptcy. Down to $.92 from 42-week of $6.95.

Encysive Pharmaceuticals (ENCY) Competitor’s pulmonary arterial hypertension drug wins approval, cuts most of staff, puts in a new CEO. Nuff said. Down to $1.71 from 52-week high of $7.10.

Human Genome Sciences (HGSI) Lehman Bros cuts stock on worries about the potential of its lupus drug candidate. Falls to $8.90 from 52-week high of $13.06.

Douglas A. McIntyre

Posted on: June 26, 2007 – 3:06 pm in Uncategorized, , , , , , , , , ,

Pre-Market Stock News (June 26, 2007)

(BEXP) Brigham Exploration increased natural gas production guidance from 42-45MCF to 44-46MCF.
(BLK) Blackrock will acquire the fund of funds business of Quellos for up to $1.7 Billion.
(BSC) Bear Stearns has report in WSJ that it is reluctant to bail out a second hedge fund from last year.
(CERS) Cerus announced a supply pact for its INTERCEPT blood system for platelets to French national blood service.
(EAS) Energy East $28.50 buyout from Spain
(ENCY) Encysive Pharma traded up on new CEO replacement.
(EYE) Advanced Medical Optics lowered 2007-2008 EPS guidance below consensus due to recall of its MoisturePlus.
(GGP) General Growth Properties will replace Mellon in S&P 500 after close on Friday June 29.
(GILT) Gilat Satellite gets SkyEdge broadband satellite network.
(ITT) ITT Industries is acquiring international Motion Control for $395 million.
(IXYS) IXYS Corp. lowered revenue target to $70 to $72 Million from $74.99 Million.
(LEN) Lennar posted a loss instead of a small gain, and revenues were down more than 30%; shares indicated down 2-5%.
(MO) Altria plans to maximize its savings on tobacco production; will see pre-tax savings of $355 Million.
(OMC) Omnicom trading ex-split to reflect a 2-1 stock split.
(OPTT) Ocean Power Tech named a new COO.
(RAIL) Freightcar America put EPS at $0.85 to $0.95 vs $1.18 estimate; announced new 1900 hopper railcar orders.
(RDYN) Replidyne announced positive Phase I results for topical antibiotic REP8839.
(SCMM) SCM Micro sees revenues down approximately 20%.
(SWSI) Superior Well Services announced that officers David Wallace, Jacob Linaberger and Rhys Reese each adopted 10b5-1 stock trading plans.
(TEK) Tektronix increased share buyback plan for $350 million worth of shares.
(TGT) Target guided sales to lower end of a 3-5% range.
(TLCV) TLC Vision purchased 20 million at average $5.75 per share.
(ULBI) Ultralife Batteries announced orders valued at approx $1.8 million to supply batteries and chargers to a major defense contractor.
(VMSI) Ventana gets $75 buyout offer from Roche, although Ventana declined talks.

Jon C. Ogg
June 26, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 26, 2007 – 6:59 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , , , , , ,

Pre-Market Stock News (June 18, 2007)

(AA) An ALCOA bid from BHP may be kindled according to numerous M&A reports.
(ADVNA) Advanta trades ex-split to reflect a 3-2 stock split.
(AGU) Agrium said earnings will be at or above the upper end of its $1.45 to $1.55 range.
(BBI) Blockbuster is going to favor the Blu-Ray HD discs.
(BNHNA) Benihana $0.35 EPS vs $0.30e.
(BWLD) Buffalo Wild Wings trades ex-split to reflect a 2-1 stock split.
(CEPH) Cephalon received FDA Marketing approval of Nuvigil for excessive sleepiness.
(CVTX) CV Therapeutics traded up on Cramer recommendation.
(DJ) Dow Jones may get a rival bid from Pearson and General Electric.
(ECIL) ECI Telecom in discussions for potential takeovers at $10.00 per share.
(ENCY) Encysive Pharma trading down 50%; announced third ‘approvable’letter from FDA for Thelin for treating pulmonary arterial hypertension, but it did not demonstrate the evidence of effectiveness needed for approval and may have to drastically cut costs.
(ESC) Emeritus Corp announces a 10.5 million share common stock offering; 9 million shares were from the company and 1.5 million from selling shareholders.
(FRN) Friendly Ice Cream going private at $15.50.
(FTEK) Fuel-Tech gets two orders totaling $2 million.
(GCO) Genesco gets $54.50 per share offer and buyout from Finish Line.
(KERX) Keryx Bio announced its CFO is resigning.
(LXRX) Lexicon Pharma secured a major investment in the company as a two part investment: $205 million and $60 million.
(MSFT) Microsoft making investment in Chinese television and media makers to change IPTV to Mediaroom.
(NVDA) NVIDIA noted as speculative chip play by Cramer.
(OBAS) Optibase won encoder pact from Huawei for IPTV.
(PAY) Verifone announced a $275 million senior convertible note offering.
(THRM) Thermage says FDA clears indication for Thermacool system.
(VICL) Vical licensee AnGes MG announces positive results of Phase 3 angiogenesis trial in Japan.
(VRAZ) Veraz platform chosen by Golden Telecom for an upgrade of its TDM network to a next-generation network.
(XFML) Xinhua Finance Media wins contract to re-brand Hebei Movie & Drama TV channel.

Jon C. Ogg
June 18, 2007

Posted on: June 18, 2007 – 6:53 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , , , , , , ,

Earlybird Analyst Calls (June 18, 2007)

ADP started as Sector Perform at CIBC.
ANDW cut to Neutral at B of A.
ASN cut to Sector Perform at RBC.
CKFR raised to Outperform at CIBC.
CPS cut to Sector Perform at CIBC.
EFD cut to Sell at Citigroup.
ENCY cut to Underperform at Rodman & Renshaw.
FCS raised to Outperform at RWBaird.
FIS started as Outperform at CIBC.
FISV raised to Sector Perform at CIBC.
GME raised to Overweight at JPMorgan.
GPN started as Sector Perform at CIBC.
KDN raised to Buy at KeyBanc/McDonald.
KYPH cut to Market Perform at Wachovia.
NATI raised to Overweight at JPMorgan.
TEK raised to Overweight at JPMorgan.
WDC cut to Neutral at JPMorgan.

Jon C. Ogg
June 18, 2007

Posted on: June 18, 2007 – 6:23 am in Analyst Calls, , , , , , , , , , , , , , , , ,